ENTRY       mmu05202                    Pathway
NAME        Transcriptional misregulation in cancer - Mus musculus (mouse)
DESCRIPTION In tumor cells, genes encoding transcription factors (TFs) are often amplified, deleted, rearranged via chromosomal translocation and inversion, or subjected to point mutations that result in a gain- or loss-of- function. In hematopoietic cancers and solid tumors, the translocations and inversions increase or deregulate transcription of the oncogene. Recurrent chromosome translocations generate novel fusion oncoproteins, which are common in myeloid cancers and soft-tissue sarcomas. The fusion proteins have aberrant transcriptional function compared to their wild-type counterparts. These fusion transcription factors alter expression of target genes, and thereby result in a variety of altered cellular properties that contribute to the tumourigenic process.
CLASS       Human Diseases; Cancer: overview
PATHWAY_MAP mmu05202  Transcriptional misregulation in cancer
ORGANISM    Mus musculus (mouse) [GN:mmu]
GENE        12394  Runx1; runt related transcription factor 1 [KO:K08367]
            12978  Csf1r; colony stimulating factor 1 receptor [KO:K05090] [EC:2.7.10.1]
            17523  Mpo; myeloperoxidase [KO:K10789] [EC:1.11.2.2]
            12981  Csf2; colony stimulating factor 2 (granulocyte-macrophage) [KO:K05427]
            16187  Il3; interleukin 3 [KO:K04736]
            12395  Runx1t1; RUNX1 translocation partner 1 [KO:K10053]
            15182  Hdac2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98]
            433759  Hdac1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98]
            20466  Sin3a; transcriptional regulator, SIN3A (yeast) [KO:K11644]
            20185  Ncor1; nuclear receptor co-repressor 1 [KO:K04650]
            12606  Cebpa; CCAAT/enhancer binding protein (C/EBP), alpha [KO:K09055]
            18627  Per2; period circadian clock 2 [KO:K02633]
            20375  Spi1; spleen focus forming virus (SFFV) proviral integration oncogene [KO:K09438]
            12475  Cd14; CD14 antigen [KO:K04391]
            16409  Itgam; integrin alpha M [KO:K06461]
            14129  Fcgr1; Fc receptor, IgG, high affinity I [KO:K06498]
            16480  Jup; junction plakoglobin [KO:K10056]
            18854  Pml; promyelocytic leukemia [KO:K10054]
            19401  Rara; retinoic acid receptor, alpha [KO:K08527]
            12428  Ccna2; cyclin A2 [KO:K06627]
            12427  Ccna1; cyclin A1 [KO:K06627]
            110794  Cebpe; CCAAT/enhancer binding protein (C/EBP), epsilon [KO:K10051]
            12047  Bcl2a1d; B cell leukemia/lymphoma 2 related protein A1d [KO:K02162]
            12044  Bcl2a1a; B cell leukemia/lymphoma 2 related protein A1a [KO:K02162]
            12045  Bcl2a1b; B cell leukemia/lymphoma 2 related protein A1b [KO:K02162]
            12046  Bcl2a1c; B cell leukemia/lymphoma 2 related protein A1c [KO:K02162]
            235320  Zbtb16; zinc finger and BTB domain containing 16 [KO:K10055]
            17869  Myc; myelocytomatosis oncogene [KO:K04377]
            67603  Dusp6; dual specificity phosphatase 6 [KO:K21946] [EC:3.1.3.16 3.1.3.48]
            21423  Tcf3; transcription factor 3 [KO:K09063]
            18514  Pbx1; pre B cell leukemia homeobox 1 [KO:K09355]
            93735  Wnt16; wingless-type MMTV integration site family, member 16 [KO:K01558]
            14011  Etv6; ets variant 6 [KO:K03211]
            13237  Defa3; defensin, alpha, 3 [KO:K05230]
            13239  Defa5; defensin, alpha, 5 [KO:K05230]
            13240  Defa6; defensin, alpha, 6 [KO:K05230]
            382059  Defa22; defensin, alpha, 22 [KO:K05230]
            66298  Defa21; defensin, alpha, 21 [KO:K05230]
            68009  Defa20; defensin, alpha, 20 [KO:K05230]
            13216  Defa1; defensin, alpha 1 [KO:K05230]
            13218  Defa29; defensin, alpha, 29 [KO:K05230]
            13219  Defa-rs10; defensin, alpha, related sequence 10 [KO:K05230]
            13221  Defa-rs12; defensin, alpha, related sequence 12 [KO:K05230]
            13222  Defa-rs2; defensin, alpha, related sequence 2 [KO:K05230]
            13226  Defa31; defensin, alpha, 31 [KO:K05230]
            382000  Defa39; defensin, alpha, 39 [KO:K05230]
            497114  Defa23; defensin, alpha, 23 [KO:K05230]
            13238  Defa4; defensin, alpha, 4 [KO:K05230]
            100294660  Defa2; defensin, alpha, 2 [KO:K05230]
            23855  Defa17; defensin, alpha, 17 [KO:K05230]
            100041890  Defa32; defensin, alpha, 32 [KO:K05230]
            100505096  Defa33; defensin, alpha, 33 [KO:K05230]
            100041811  Defa27; defensin, alpha, 27 [KO:K05230]
            626708  Defa26; defensin, alpha, 26 [KO:K05230]
            100041895  Defa37; defensin, alpha, 37 [KO:K05230]
            100041759  Defa41; defensin, alpha, 41 [KO:K05230]
            100041787  Defa40; defensin, alpha, 40 [KO:K05230]
            100038927  Defa30; defensin, alpha, 30 [KO:K05230]
            100041688  Defa35; defensin, alpha, 35 [KO:K05230]
            100041952  Defa34; defensin, alpha, 34 [KO:K05230]
            13236  Defa25; defensin, alpha, 25 [KO:K05230]
            100862126  Defa36; defensin, alpha, 36 [KO:K05230]
            503491  Defa24; defensin, alpha, 24 [KO:K05230]
            626682  Defa28; defensin, alpha, 28 [KO:K05230]
            665927  Defa42; defensin, alpha, 42 [KO:K05230]
            634825  Defa38; defensin, alpha, 38 [KO:K05230]
            100503970  cDNA sequence AY761185 [KO:K05230]
            665956  Defa43; defensin, alpha, 43 [KO:K05230]
            13223  Defa-rs4; defensin, alpha,, related sequence 4 [KO:K05230]
            50701  Elane; elastase, neutrophil expressed [KO:K01327] [EC:3.4.21.37]
            14939  Gzmb; granzyme B [KO:K01353] [EC:3.4.21.79]
            214162  Kmt2a; lysine (K)-specific methyltransferase 2A [KO:K09186] [EC:2.1.1.354]
            17355  Aff1; AF4/FMR2 family, member 1 [KO:K15184]
            107951  Cdk9; cyclin-dependent kinase 9 (CDC2-related kinase) [KO:K02211] [EC:2.7.11.22 2.7.11.23]
            12455  Ccnt1; cyclin T1 [KO:K15188]
            72949  Ccnt2; cyclin T2 [KO:K15188]
            64144  Mllt1; myeloid/lymphoid or mixed-lineage leukemia; translocated to, 1 [KO:K15187]
            70122  Mllt3; myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3 [KO:K15187]
            208266  Dot1l; DOT1-like, histone H3 methyltransferase (S. cerevisiae) [KO:K11427] [EC:2.1.1.360]
            16909  Lmo2; LIM domain only 2 [KO:K15612]
            18516  Pbx3; pre B cell leukemia homeobox 3 [KO:K15610]
            12393  Runx2; runt related transcription factor 2 [KO:K09278]
            17125  Smad1; SMAD family member 1 [KO:K04676]
            16599  Klf3; Kruppel-like factor 3 (basic) [KO:K15605]
            17260  Mef2c; myocyte enhancer factor 2C [KO:K04454]
            15405  Hoxa9; homeobox A9 [KO:K21950]
            15395  Hoxa10; homeobox A10 [KO:K17443]
            108829  Jmjd1c; jumonji domain containing 1C [KO:K11449] [EC:1.14.11.-]
            15364  Hmga2; high mobility group AT-hook 2 [KO:K09283]
            22289  Kdm6a; lysine (K)-specific demethylase 6A [KO:K11447] [EC:1.14.11.68]
            22290  Uty; ubiquitously transcribed tetratricopeptide repeat containing, Y-linked [KO:K11447] [EC:1.14.11.68]
            109115  Supt3; SPT3, SAGA and STAGA complex component [KO:K11313]
            19126  Prom1; prominin 1 [KO:K06532]
            14255  Flt3; FMS-like tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1]
            140780  Bmp2k; BMP2 inducible kinase [KO:K08854] [EC:2.7.11.1]
            16001  Igf1r; insulin-like growth factor I receptor [KO:K05087] [EC:2.7.10.1]
            12576  Cdkn1b; cyclin-dependent kinase inhibitor 1B [KO:K06624]
            18647  Cdk14; cyclin-dependent kinase 14 [KO:K08821] [EC:2.7.11.22]
            17268  Meis1; Meis homeobox 1 [KO:K15613]
            15396  Hoxa11; homeobox A11 [KO:K21951]
            20471  Six1; sine oculis-related homeobox 1 [KO:K15614]
            20474  Six4; sine oculis-related homeobox 4 [KO:K15615]
            14048  Eya1; EYA transcriptional coactivator and phosphatase 1 [KO:K15616] [EC:3.1.3.48]
            12580  Cdkn2c; cyclin dependent kinase inhibitor 2C [KO:K06622]
            15446  Hpgd; hydroxyprostaglandin dehydrogenase 15 (NAD) [KO:K00069] [EC:1.1.1.141]
            53623  Gria3; glutamate receptor, ionotropic, AMPA3 (alpha 3) [KO:K05199]
            53618  Fut8; fucosyltransferase 8 [KO:K00717] [EC:2.4.1.68]
            27140  Tlx3; T cell leukemia, homeobox 3 [KO:K15607]
            21908  Tlx1; T cell leukemia, homeobox 1 [KO:K09340]
            58208  Bcl11b; B cell leukemia/lymphoma 11B [KO:K22046]
            16825  Ldb1; LIM domain binding 1 [KO:K15617]
            17095  Lyl1; lymphoblastomic leukemia 1 [KO:K15604]
            15242  Hhex; hematopoietically expressed homeobox [KO:K08024]
            19208  Ptcra; pre T cell antigen receptor alpha [KO:K06056]
            19696  Rel; reticuloendotheliosis oncogene [KO:K09254]
            12444  Ccnd2; cyclin D2 [KO:K10151]
            11797  Birc2; baculoviral IAP repeat-containing 2 [KO:K16060]
            11796  Birc3; baculoviral IAP repeat-containing 3 [KO:K16060]
            22029  Traf1; TNF receptor-associated factor 1 [KO:K03172]
            12048  Bcl2l1; BCL2-like 1 [KO:K04570]
            12524  Cd86; CD86 antigen [KO:K05413]
            21939  Cd40; CD40 antigen [KO:K03160]
            12053  Bcl6; B cell leukemia/lymphoma 6 [KO:K15618]
            17132  Maf; avian musculoaponeurotic fibrosarcoma oncogene homolog [KO:K09035]
            16421  Itgb7; integrin beta 7 [KO:K06590]
            107823  Nsd2; nuclear receptor binding SET domain protein 2 [KO:K11424] [EC:2.1.1.357]
            15078  H3f3a; H3.3 histone A [KO:K11253]
            15081  H3f3b; H3.3 histone B [KO:K11253]
            625328  H3f3c; H3 histone, family 3C [KO:K11253]
            667250  Gm12657; predicted gene 12657 [KO:K11253]
            319152  H3c10; H3 clustered histone 10 [KO:K11253]
            15077  H3c14; H3 clustered histone 14 [KO:K11253]
            260423  H3c7; H3 clustered histone 7 [KO:K11253]
            319148  H3c3; H3 clustered histone 3 [KO:K11253]
            319149  H3c4; H3 clustered histone 4 [KO:K11253]
            319150  H3c2; H3 clustered histone 2 [KO:K11253]
            319151  H3c6; H3 clustered histone 6 [KO:K11253]
            319153  H3c11; H3 clustered histone 11 [KO:K11253]
            319154  H3c13; H3 clustered histone 13 [KO:K11253]
            360198  H3c1; H3 clustered histone 1 [KO:K11253]
            97114  H3c15; H3 clustered histone 15 [KO:K11253]
            97908  H3c8; H3 clustered histone 8 [KO:K11253]
            382523  H3f4; H3.4 histone [KO:K11253]
            18507  Pax5; paired box 5 [KO:K09383]
            18510  Pax8; paired box 8 [KO:K09293]
            19016  Pparg; peroxisome proliferator activated receptor gamma [KO:K08530]
            20181  Rxra; retinoid X receptor alpha [KO:K08524]
            20182  Rxrb; retinoid X receptor beta [KO:K08525]
            20183  Rxrg; retinoid X receptor gamma [KO:K08526]
            94315  Prcc; papillary renal cell carcinoma (translocation-associated) [KO:K13105]
            209446  Tfe3; transcription factor E3 [KO:K09105]
            12575  Cdkn1a; cyclin-dependent kinase inhibitor 1A (P21) [KO:K06625]
            50528  Tmprss2; transmembrane protease, serine 2 [KO:K09633] [EC:3.4.21.-]
            13876  Erg; ETS transcription factor [KO:K09435]
            18792  Plau; plasminogen activator, urokinase [KO:K01348] [EC:3.4.21.73]
            18791  Plat; plasminogen activator, tissue [KO:K01343] [EC:3.4.21.68]
            17392  Mmp3; matrix metallopeptidase 3 [KO:K01394] [EC:3.4.24.17]
            17395  Mmp9; matrix metallopeptidase 9 [KO:K01403] [EC:3.4.24.35]
            21417  Zeb1; zinc finger E-box binding homeobox 1 [KO:K09299]
            16178  Il1r2; interleukin 1 receptor, type II [KO:K04387]
            20732  Spint1; serine protease inhibitor, Kunitz type 1 [KO:K15619]
            14009  Etv1; ets variant 1 [KO:K09431]
            18612  Etv4; ets variant 4 [KO:K15592]
            104156  Etv5; ets variant 5 [KO:K15593]
            212980  Slc45a3; solute carrier family 45, member 3 [KO:K15379]
            13714  Elk4; ELK4, member of ETS oncogene family [KO:K04376]
            13207  Ddx5; DEAD box helicase 5 [KO:K12823] [EC:3.6.4.13]
            18109  Mycn; v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived [KO:K09109]
            17187  Max; Max protein [KO:K04453]
            17246  Mdm2; transformed mouse 3T3 cell double minute 2 [KO:K06643] [EC:2.3.2.27]
            14083  Ptk2; PTK2 protein tyrosine kinase 2 [KO:K05725] [EC:2.7.10.2]
            22059  Trp53; transformation related protein 53 [KO:K04451]
            12151  Bmi1; Bmi1 polycomb ring finger oncogene [KO:K11459]
            20683  Sp1; trans-acting transcription factor 1 [KO:K04684]
            22642  Zbtb17; zinc finger and BTB domain containing 17 [KO:K10500]
            18211  Ntrk1; neurotrophic tyrosine kinase, receptor, type 1 [KO:K03176] [EC:2.7.10.1]
            18053  Ngfr; nerve growth factor receptor (TNFR superfamily, member 16) [KO:K02583]
            17283  Men1; multiple endocrine neoplasia 1 [KO:K14970]
            14030  Ewsr1; Ewing sarcoma breakpoint region 1 [KO:K13209]
            14247  Fli1; Friend leukemia integration 1 [KO:K09436]
            16000  Igf1; insulin-like growth factor 1 [KO:K05459]
            15902  Id2; inhibitor of DNA binding 2 [KO:K17693]
            21813  Tgfbr2; transforming growth factor, beta receptor II [KO:K04388] [EC:2.7.11.30]
            16009  Igfbp3; insulin-like growth factor binding protein 3 [KO:K10138]
            260298  Fev; FEV transcription factor, ETS family member [KO:K09437]
            11908  Atf1; activating transcription factor 1 [KO:K09053]
            11864  Arnt2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589]
            11920  Atm; ataxia telangiectasia mutated [KO:K04728] [EC:2.7.11.1]
            17342  Mitf; melanogenesis associated transcription factor [KO:K09455]
            22431  Wt1; Wilms tumor 1 homolog [KO:K09234]
            18590  Pdgfa; platelet derived growth factor, alpha [KO:K04359]
            16185  Il2rb; interleukin 2 receptor, beta chain [KO:K05069]
            545192  Baiap3; BAI1-associated protein 3 [KO:K15621]
            21912  Tspan7; tetraspanin 7 [KO:K06571]
            17349  Mlf1; myeloid leukemia factor 1 [KO:K15622]
            18124  Nr4a3; nuclear receptor subfamily 4, group A, member 3 [KO:K08559]
            70439  Taf15; TATA-box binding protein associated factor 15 [KO:K14651]
            233908  Fus; fused in sarcoma [KO:K13098]
            13198  Ddit3; DNA-damage inducible transcript 3 [KO:K04452]
            12608  Cebpb; CCAAT/enhancer binding protein (C/EBP), beta [KO:K10048]
            16193  Il6; interleukin 6 [KO:K05405]
            80859  Nfkbiz; nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta [KO:K14242]
            18033  Nfkb1; nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 [KO:K02580]
            19697  Rela; v-rel reticuloendotheliosis viral oncogene homolog A (avian) [KO:K04735]
            18509  Pax7; paired box 7 [KO:K09381]
            18505  Pax3; paired box 3 [KO:K09381]
            56458  Foxo1; forkhead box O1 [KO:K07201]
            14254  Flt1; FMS-like tyrosine kinase 1 [KO:K05096] [EC:2.7.10.1]
            268996  Ss18; SS18, nBAF chromatin remodeling complex subunit [KO:K15623]
            387586  Ssxb5; synovial sarcoma, X member B5 [KO:K15624]
            56312  Nupr1; nuclear protein transcription regulator 1 [KO:K15626]
            68938  Aspscr1; alveolar soft part sarcoma chromosome region, candidate 1 (human) [KO:K15627]
            17295  Met; met proto-oncogene [KO:K05099] [EC:2.7.10.1]
            13197  Gadd45a; growth arrest and DNA-damage-inducible 45 alpha [KO:K04402]
            17873  Gadd45b; growth arrest and DNA-damage-inducible 45 beta [KO:K04402]
            23882  Gadd45g; growth arrest and DNA-damage-inducible 45 gamma [KO:K04402]
            12028  Bax; BCL2-associated X protein [KO:K02159]
            12018  Bak1; BCL2-antagonist/killer 1 [KO:K14021]
            107986  Ddb2; damage specific DNA binding protein 2 [KO:K10140]
            27015  Polk; polymerase (DNA directed), kappa [KO:K03511] [EC:2.7.7.7]
REFERENCE   PMID:11607818
  AUTHORS   Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, Sciurpi MT, Gelmetti V, Riganelli D, Minucci S, Fagioli M, Pelicci PG
  TITLE     Common themes in the pathogenesis of acute myeloid leukemia.
  JOURNAL   Oncogene 20:5680-94 (2001)
            DOI:10.1038/sj.onc.1204642
REFERENCE   PMID:12032780
  AUTHORS   Scandura JM, Boccuni P, Cammenga J, Nimer SD
  TITLE     Transcription factor fusions in acute leukemia: variations on a theme.
  JOURNAL   Oncogene 21:3422-44 (2002)
            DOI:10.1038/sj.onc.1205315
REFERENCE   PMID:12529654
  AUTHORS   Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C
  TITLE     New mechanisms of AML1 gene alteration in hematological malignancies.
  JOURNAL   Leukemia 17:9-16 (2003)
            DOI:10.1038/sj.leu.2402766
REFERENCE   PMID:10717473
  AUTHORS   Lutterbach B, Hiebert SW
  TITLE     Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.
  JOURNAL   Gene 245:223-35 (2000)
            DOI:10.1016/S0378-1119(00)00014-7
REFERENCE   PMID:19075268
  AUTHORS   Koschmieder S, Halmos B, Levantini E, Tenen DG
  TITLE     Dysregulation of the C/EBPalpha differentiation pathway in human cancer.
  JOURNAL   J Clin Oncol 27:619-28 (2009)
            DOI:10.1200/JCO.2008.17.9812
REFERENCE   PMID:11340171
  AUTHORS   Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG
  TITLE     c-Myc is a critical target for c/EBPalpha in granulopoiesis.
  JOURNAL   Mol Cell Biol 21:3789-806 (2001)
            DOI:10.1128/MCB.21.11.3789-3806.2001
REFERENCE   PMID:15985538
  AUTHORS   Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP
  TITLE     Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia.
  JOURNAL   Blood 106:2827-36 (2005)
            DOI:10.1182/blood-2005-01-0358
REFERENCE   PMID:12393465
  AUTHORS   Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G
  TITLE     The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
  JOURNAL   Blood 101:270-7 (2003)
            DOI:10.1182/blood-2002-04-1288
REFERENCE   PMID:12130514
  AUTHORS   Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG
  TITLE     Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
  JOURNAL   Blood 100:998-1007 (2002)
            DOI:10.1182/blood.V100.3.998
REFERENCE   PMID:15160934
  AUTHORS   Jing Y
  TITLE     The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
  JOURNAL   Leuk Lymphoma 45:639-48 (2004)
            DOI:10.1080/10428190310001609933
REFERENCE   PMID:15024077
  AUTHORS   Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H
  TITLE     Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
  JOURNAL   Mol Cell Biol 24:2890-904 (2004)
            DOI:10.1128/MCB.24.7.2890-2904.2004
REFERENCE   PMID:19855079
  AUTHORS   Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, Leiva M, Ablain J, Ambardekar C, McConnell MJ, Dick JE, Licht JD
  TITLE     Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
  JOURNAL   Blood 114:5499-511 (2009)
            DOI:10.1182/blood-2009-03-206524
REFERENCE   PMID:10500199
  AUTHORS   McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C
  TITLE     Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia.
  JOURNAL   Proc Natl Acad Sci U S A 96:11464-9 (1999)
            DOI:10.1073/pnas.96.20.11464
REFERENCE   PMID:15156184
  AUTHORS   Zelent A, Greaves M, Enver T
  TITLE     Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia.
  JOURNAL   Oncogene 23:4275-83 (2004)
            DOI:10.1038/sj.onc.1207672
REFERENCE   PMID:14630078
  AUTHORS   Sawinska M, Ladon D
  TITLE     Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia.
  JOURNAL   Leuk Res 28:35-42 (2004)
            DOI:10.1016/S0145-2126(03)00160-7
REFERENCE   PMID:19141473
  AUTHORS   Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, Croce CM, Nakamura T, Canaani E, Young RA
  TITLE     Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.
  JOURNAL   Genes Dev 22:3403-8 (2008)
            DOI:10.1101/gad.1741408
REFERENCE   PMID:16169901
  AUTHORS   Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, Zeleznik-Le NJ
  TITLE     The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
  JOURNAL   Proc Natl Acad Sci U S A 102:14028-33 (2005)
            DOI:10.1073/pnas.0506464102
REFERENCE   PMID:21518926
  AUTHORS   Wang QF, Wu G, Mi S, He F, Wu J, Dong J, Luo RT, Mattison R, Kaberlein JJ, Prabhakar S, Ji H, Thirman MJ
  TITLE     MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
  JOURNAL   Blood 117:6895-905 (2011)
            DOI:10.1182/blood-2010-12-324699
REFERENCE   PMID:14701735
  AUTHORS   Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U, Borkhardt A, Chanda SK, Walker J, Soden R, Hess JL, Slany RK
  TITLE     Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
  JOURNAL   Mol Cell Biol 24:617-28 (2004)
            DOI:10.1128/MCB.24.2.617-628.2004
REFERENCE   PMID:19133982
  AUTHORS   Riz I, Hawley TS, Johnston H, Hawley RG
  TITLE     Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis.
  JOURNAL   Br J Haematol 145:140-3 (2009)
            DOI:10.1111/j.1365-2141.2008.07556.x
REFERENCE   PMID:12511414
  AUTHORS   Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, Parwaresch RM, Lichter P, Siebert R, Mooller P
  TITLE     Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma.
  JOURNAL   Blood 101:3681-6 (2003)
            DOI:10.1182/blood-2002-08-2577
REFERENCE   PMID:11313274
  AUTHORS   Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C
  TITLE     Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.
  JOURNAL   Blood 97:2798-807 (2001)
            DOI:10.1182/blood.V97.9.2798
REFERENCE   PMID:12670461
  AUTHORS   Zuzel M, Cawley JC.
  TITLE     The biology of hairy cells.
  JOURNAL   Best Pract Res Clin Haematol 16:1-13 (2003)
            DOI:10.1016/S1521-6926(02)00082-8
REFERENCE   PMID:14998494
  AUTHORS   Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM
  TITLE     Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
  JOURNAL   Cancer Cell 5:191-9 (2004)
            DOI:10.1016/S1535-6108(04)00019-4
REFERENCE   PMID:20974671
  AUTHORS   Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD
  TITLE     The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
  JOURNAL   Blood 117:211-20 (2011)
            DOI:10.1182/blood-2010-07-298349
REFERENCE   PMID:19059936
  AUTHORS   Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, Morgan GJ
  TITLE     MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
  JOURNAL   Haematologica 94:78-86 (2009)
            DOI:10.3324/haematol.13426
REFERENCE   PMID:10350329
  AUTHORS   Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera R
  TITLE     Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32).
  JOURNAL   Leuk Lymphoma 34:25-33 (1999)
            DOI:10.3109/10428199909083377
REFERENCE   PMID:10784387
  AUTHORS   Ohno H, Ueda C, Akasaka T
  TITLE     The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
  JOURNAL   Leuk Lymphoma 36:435-45 (2000)
            DOI:10.3109/10428190009148390
REFERENCE   PMID:19233641
  AUTHORS   Prensner JR, Chinnaiyan AM
  TITLE     Oncogenic gene fusions in epithelial carcinomas.
  JOURNAL   Curr Opin Genet Dev 19:82-91 (2009)
            DOI:10.1016/j.gde.2008.11.008
REFERENCE   PMID:19406209
  AUTHORS   Brenner JC, Chinnaiyan AM
  TITLE     Translocations in epithelial cancers.
  JOURNAL   Biochim Biophys Acta 1796:201-15 (2009)
            DOI:10.1016/j.bbcan.2009.04.005
REFERENCE   PMID:16946003
  AUTHORS   Reddi HV, McIver B, Grebe SK, Eberhardt NL
  TITLE     The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.
  JOURNAL   Endocrinology 148:932-5 (2007)
            DOI:10.1210/en.2006-0926
REFERENCE   PMID:19422821
  AUTHORS   Medendorp K, van Groningen JJ, Vreede L, Hetterschijt L, Brugmans L, van den Hurk WH, van Kessel AG
  TITLE     The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
  JOURNAL   Exp Cell Res 315:2399-409 (2009)
            DOI:10.1016/j.yexcr.2009.04.022
REFERENCE   PMID:18563191
  AUTHORS   Kumar-Sinha C, Tomlins SA, Chinnaiyan AM
  TITLE     Recurrent gene fusions in prostate cancer.
  JOURNAL   Nat Rev Cancer 8:497-511 (2008)
            DOI:10.1038/nrc2402
REFERENCE   PMID:20478527
  AUTHORS   Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM
  TITLE     An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
  JOURNAL   Cancer Cell 17:443-54 (2010)
            DOI:10.1016/j.ccr.2010.03.018
REFERENCE   PMID:21747944
  AUTHORS   Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R
  TITLE     TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.
  JOURNAL   PLoS One 6:e21650 (2011)
            DOI:10.1371/journal.pone.0021650
REFERENCE   PMID:17505060
  AUTHORS   Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L
  TITLE     ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.
  JOURNAL   Mol Endocrinol 21:1835-46 (2007)
            DOI:10.1210/me.2006-0480
REFERENCE   PMID:18172298
  AUTHORS   Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM
  TITLE     Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
  JOURNAL   Cancer Res 68:73-80 (2008)
            DOI:10.1158/0008-5472.CAN-07-5352
REFERENCE   PMID:21849159
  AUTHORS   Westermark UK, Wilhelm M, Frenzel A, Henriksson MA
  TITLE     The MYCN oncogene and differentiation in neuroblastoma.
  JOURNAL   Semin Cancer Biol 21:256-66 (2011)
            DOI:10.1016/j.semcancer.2011.08.001
REFERENCE   PMID:20153925
  AUTHORS   Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA
  TITLE     MYCN oncoprotein targets and their therapeutic potential.
  JOURNAL   Cancer Lett 293:144-57 (2010)
            DOI:10.1016/j.canlet.2010.01.015
REFERENCE   PMID:15644444
  AUTHORS   Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM
  TITLE     The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
  JOURNAL   Proc Natl Acad Sci U S A 102:731-6 (2005)
            DOI:10.1073/pnas.0405495102
REFERENCE   PMID:20190806
  AUTHORS   Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M, Okimoto Y, Fujimura Y, Koseki H, Kohno Y, Nakagawara A, Kamijo T
  TITLE     Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
  JOURNAL   Oncogene 29:2681-90 (2010)
            DOI:10.1038/onc.2010.22
REFERENCE   PMID:20145147
  AUTHORS   Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA
  TITLE     p53 is a direct transcriptional target of MYCN in neuroblastoma.
  JOURNAL   Cancer Res 70:1377-88 (2010)
            DOI:10.1158/0008-5472.CAN-09-2598
REFERENCE   PMID:17327229
  AUTHORS   Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG, Golubovskaya VM
  TITLE     N-MYC regulates focal adhesion kinase expression in human neuroblastoma.
  JOURNAL   J Biol Chem 282:12503-16 (2007)
            DOI:10.1074/jbc.M701450200
REFERENCE   PMID:21123453
  AUTHORS   Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Della Valle G, Perini G
  TITLE     A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
  JOURNAL   Cancer Res 71:404-12 (2011)
            DOI:10.1158/0008-5472.CAN-10-2627
REFERENCE   PMID:17024155
  AUTHORS   Dreijerink KM, Hoppener JW, Timmers HM, Lips CJ
  TITLE     Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation.
  JOURNAL   Nat Clin Pract Endocrinol Metab 2:562-70 (2006)
            DOI:10.1038/ncpendmet0292
REFERENCE   PMID:19075677
  AUTHORS   Wu X, Hua X
  TITLE     Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective.
  JOURNAL   Curr Mol Med 8:805-15 (2008)
            DOI:10.2174/156652408786733702
REFERENCE   PMID:19564705
  AUTHORS   Sakurai A, Murakami A, Sano K, Uchino S, Fukushima Y
  TITLE     Unusual clinical and pathological presentation of a neuroendocrine tumor in a patient with multiple endocrine neoplasia type 1.
  JOURNAL   Endocr J 56:887-95 (2009)
            DOI:10.1507/endocrj.K09E-126
REFERENCE   PMID:17222504
  AUTHORS   Yang Y, Hua X
  TITLE     In search of tumor suppressing functions of menin.
  JOURNAL   Mol Cell Endocrinol 265-266:34-41 (2007)
            DOI:10.1016/j.mce.2006.12.032
REFERENCE   PMID:15826838
  AUTHORS   Aman P
  TITLE     Fusion oncogenes in tumor development.
  JOURNAL   Semin Cancer Biol 15:236-43 (2005)
            DOI:10.1016/j.semcancer.2005.01.009
REFERENCE   PMID:12527902
  AUTHORS   Fukuma M, Okita H, Hata J, Umezawa A
  TITLE     Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma.
  JOURNAL   Oncogene 22:1-9 (2003)
            DOI:10.1038/sj.onc.1206055
REFERENCE   PMID:18648544
  AUTHORS   Cironi L, Riggi N, Provero P, Wolf N, Suva ML, Suva D, Kindler V, Stamenkovic I
  TITLE     IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.
  JOURNAL   PLoS One 3:e2634 (2008)
            DOI:10.1371/journal.pone.0002634
REFERENCE   PMID:17250957
  AUTHORS   Riggi N, Stamenkovic I.
  TITLE     The Biology of Ewing sarcoma.
  JOURNAL   Cancer Lett 254:1-10 (2007)
            DOI:10.1016/j.canlet.2006.12.009
REFERENCE   PMID:20490326
  AUTHORS   Jedlicka P
  TITLE     Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions.
  JOURNAL   Int J Clin Exp Pathol 3:338-47 (2010)
REFERENCE   PMID:19738075
  AUTHORS   Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J
  TITLE     Advances in Ewing's sarcoma research: where are we now and what lies ahead?
  JOURNAL   Cancer Res 69:7140-50 (2009)
            DOI:10.1158/0008-5472.CAN-08-4041
REFERENCE   PMID:12527906
  AUTHORS   Jishage M, Fujino T, Yamazaki Y, Kuroda H, Nakamura T
  TITLE     Identification of target genes for EWS/ATF-1 chimeric transcription factor.
  JOURNAL   Oncogene 22:41-9 (2003)
            DOI:10.1038/sj.onc.1206074
REFERENCE   PMID:15826834
  AUTHORS   Gerald WL, Haber DA
  TITLE     The EWS-WT1 gene fusion in desmoplastic small round cell tumor.
  JOURNAL   Semin Cancer Biol 15:197-205 (2005)
            DOI:10.1016/j.semcancer.2005.01.005
REFERENCE   PMID:18855877
  AUTHORS   Filion C, Motoi T, Olshen AB, Lae M, Emnett RJ, Gutmann DH, Perry A, Ladanyi M, Labelle Y
  TITLE     The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.
  JOURNAL   J Pathol 217:83-93 (2009)
            DOI:10.1002/path.2445
REFERENCE   PMID:18330902
  AUTHORS   Kim S, Lee HJ, Jun HJ, Kim J
  TITLE     The hTAF II 68-TEC fusion protein functions as a strong transcriptional activator.
  JOURNAL   Int J Cancer 122:2446-53 (2008)
            DOI:10.1002/ijc.23379
REFERENCE   PMID:10537274
  AUTHORS   Sjogren H, Meis-Kindblom J, Kindblom LG, Aman P, Stenman G
  TITLE     Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.
  JOURNAL   Cancer Res 59:5064-7 (1999)
REFERENCE   PMID:15688424
  AUTHORS   Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P
  TITLE     Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
  JOURNAL   Int J Cancer 115:556-60 (2005)
            DOI:10.1002/ijc.20893
REFERENCE   PMID:18850010
  AUTHORS   Goransson M, Andersson MK, Forni C, Stahlberg A, Andersson C, Olofsson A, Mantovani R, Aman P
  TITLE     The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
  JOURNAL   Oncogene 28:270-8 (2009)
            DOI:10.1038/onc.2008.378
REFERENCE   PMID:20863376
  AUTHORS   Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PC, Bovee JV
  TITLE     Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
  JOURNAL   Mol Cancer 9:257 (2010)
            DOI:10.1186/1476-4598-9-257
REFERENCE   PMID:18457914
  AUTHORS   Linardic CM
  TITLE     PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
  JOURNAL   Cancer Lett 270:10-8 (2008)
            DOI:10.1016/j.canlet.2008.03.035
REFERENCE   PMID:11863357
  AUTHORS   Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S, Friedman TB
  TITLE     Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma.
  JOURNAL   Genomics 79:278-84 (2002)
            DOI:10.1006/geno.2002.6703
REFERENCE   PMID:17101797
  AUTHORS   Ishida M, Miyamoto M, Naitoh S, Tatsuda D, Hasegawa T, Nemoto T, Yokozeki H, Nishioka K, Matsukage A, Ohki M, Ohta T
  TITLE     The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma.
  JOURNAL   Mol Cell Biol 27:1348-55 (2007)
            DOI:10.1128/MCB.00658-06
REFERENCE   PMID:19472090
  AUTHORS   Jun HJ, Lee J, Lim do H, Park JO, Ahn G, Seo SW, Sung KS, Lim do H, Yoo KH, Choi YL
  TITLE     Expression of MET in alveolar soft part sarcoma.
  JOURNAL   Med Oncol 27:459-65 (2010)
            DOI:10.1007/s12032-009-9234-8
REFERENCE   PMID:21779514
  AUTHORS   Rivlin N, Brosh R, Oren M, Rotter V
  TITLE     Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.
  JOURNAL   Genes Cancer 2:466-74 (2011)
            DOI:10.1177/1947601911408889
REFERENCE   PMID:21765642
  AUTHORS   Suzuki K, Matsubara H
  TITLE     Recent advances in p53 research and cancer treatment.
  JOURNAL   J Biomed Biotechnol 2011:978312 (2011)
            DOI:10.1155/2011/978312
REL_PATHWAY mmu04115  p53 signaling pathway
            mmu05211  Renal cell carcinoma
            mmu05215  Prostate cancer
            mmu05216  Thyroid cancer
            mmu05221  Acute myeloid leukemia
KO_PATHWAY  ko05202
///
